Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Permanent Non-pulsatile Disabling Tinnitus (TINNOP3-DBS)
Recruiting · NCT04296097 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Grenoble
View the official record on ClinicalTrials.gov →Interventions studied
DBS
What this trial is about
This pilot study aims at evaluating the effectiveness of the treatment of unilateral or bilateral, non-pulsatile, disabling, tinnitus, without vestibular dysfunction, using Deep Brain Stimulation (DBS) of the parieto-insular right operculum 3 (OP3) in a cross-over, double study design.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Between 18 and 75 years old,
- Uni or bilateral permanent non-pulsatile tinnitus, without associated vestibular pathology, with or without hearing loss,
- Severe tinnitus resistant to treatment failure,
- Tinnitus intensity on the Visual Analog Scale (VAS) ≥ 7,
- Presenting a quality of life score on the Tinnitus Handicap Inventory (THI) questionnaire\> 76 (= grade 5),
- Social security affiliates or beneficiaries of such a scheme
- Informed and written consent signed by the patient.
Exclusion criteria
- Vestibular dysfunction (balance disorder),
- Epilepsy,
- Intercurrent serious pathology,
- Brain tumor,
- Contraindication to surgery or anesthesia,
- History of cerebral infection with herpesvirus,
- With a contraindication to the practice of MRI, MEG, Computerized Tomography (CT) scan,
- Under anticoagulants and antiaggregants (Anti vitamin K, low molecular weight heparin, aspirin and derivatives, clopidogrel antiplatelet agents and assimilated, new oral anticoagulants (NACO)) for which a therapeutic window can not be opened within 3 months before and after the surgery,
- Included in another therapeutic protocol,
- Progressive dementia or psychiatric illness,
- Presenting a suicidal risk deemed important for less than 3 months (Montgomery and Asberg depression scale (MADRS): suicidality item (item 10) score\> 2),
- Enforced hospitalisation,
- Pregnant, parturient or breastfeeding, lack of contraception in patients with the capacity to procreate,
- Subject to a legal protection measure,
- Deprived of liberty by judicial or administrative decision,
- Isolated patient without any contact in case of emergency.
Where it is running
2 locations listed.
- CLINATEC - Grenoble, France
- CLINATEC - Grenoble, France